Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab maintenance in advanced vulvar cancer
NCT07101848Phase 2Not yet recruiting
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Nov 2025
- Primary completion
- Dec 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in vulvar squamous cell carcinoma (VSCC), sponsored by Hospital Israelita Albert Einstein. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
cemiplimab
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NCT07101848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07101848.